{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:25:33Z","timestamp":1788837933104,"version":"build-2803163510"},"reference-count":237,"publisher":"European Respiratory Society (ERS)","issue":"148","content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir Rev"],"accepted":{"date-parts":[[2018,2,24]]},"published-print":{"date-parts":[[2018,6,30]]},"abstract":"<jats:p>Interstitial lung disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc). We performed a systematic review to characterise the use and validation of pulmonary function tests (PFTs) as surrogate markers for systemic sclerosis-associated interstitial lung disease (SSc-ILD) progression.<\/jats:p><jats:p>Five electronic databases were searched to identify all relevant studies. Included studies either used at least one PFT measure as a longitudinal outcome for SSc-ILD progression (<jats:italic>i.e.<\/jats:italic>outcome studies) and\/or reported at least one classical measure of validity for the PFTs in SSc-ILD (<jats:italic>i.e.<\/jats:italic>validation studies).<\/jats:p><jats:p>This systematic review included 169 outcome studies and 50 validation studies. Diffusing capacity of the lung for carbon monoxide (<jats:italic>D<\/jats:italic><jats:sub>LCO<\/jats:sub>) was cumulatively the most commonly used outcome until 2010 when it was surpassed by forced vital capacity (FVC). FVC (% predicted) was the primary endpoint in 70.4% of studies, compared to 11.3% for % predicted<jats:italic>D<\/jats:italic><jats:sub>LCO<\/jats:sub>. Only five studies specifically aimed to validate the PFTs: two concluded that<jats:italic>D<\/jats:italic><jats:sub>LCO<\/jats:sub>was the best measure of SSc-ILD extent, while the others did not favour any PFT. These studies also showed respectable validity measures for total lung capacity (TLC).<\/jats:p><jats:p>Despite the current preference for FVC, available evidence suggests that<jats:italic>D<\/jats:italic><jats:sub>LCO<\/jats:sub>and TLC should not yet be discounted as potential surrogate markers for SSc-ILD progression.<\/jats:p>","DOI":"10.1183\/16000617.0102-2017","type":"journal-article","created":{"date-parts":[[2018,5,16]],"date-time":"2018-05-16T07:25:14Z","timestamp":1526455514000},"page":"170102","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":78,"title":["Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease"],"prefix":"10.1183","volume":"27","author":[{"given":"Melissa","family":"Caron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Hoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Steele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,5,15]]},"reference":[{"key":"2024102403341469000_27.148.170102.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0806188"},{"key":"2024102403341469000_27.148.170102.2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011110-130312"},{"key":"2024102403341469000_27.148.170102.3","unstructured":"Seibold J . Scleroderma. In: Harris ED , Budd RC , Firestein GS , Genovese MC , Sergent JS , Ruddy S , Sledge CB , eds. Kelley's Textbook of Rheumatology . 7th Edn. Philadelphia, Elsevier, 2005; pp. 1279\u20131308."},{"key":"2024102403341469000_27.148.170102.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2014.12.005"},{"key":"2024102403341469000_27.148.170102.5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/acr.21583","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024102403341469000_27.148.170102.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.berh.2009.12.002"},{"key":"2024102403341469000_27.148.170102.7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-194905000-00002","article-title":"Pulmonary insufficiency; a study of 39 cases of pulmonary fibrosis","volume":"28","author":"Baldwin","year":"1949","journal-title":"Medicine (Baltimore)"},{"key":"2024102403341469000_27.148.170102.8","doi-asserted-by":"publisher","DOI":"10.1059\/0003-4819-155-8-201110180-00009"},{"key":"2024102403341469000_27.148.170102.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000097"},{"key":"2024102403341469000_27.148.170102.10","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(82)90732-X"},{"key":"2024102403341469000_27.148.170102.11","doi-asserted-by":"publisher","DOI":"10.1378\/chest.85.3.318"},{"key":"2024102403341469000_27.148.170102.12","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/00005792-198407000-00004","article-title":"Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis","volume":"63","author":"Peters-Golden","year":"1984","journal-title":"Medicine (Baltimore)"},{"key":"2024102403341469000_27.148.170102.13","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780280807"},{"key":"2024102403341469000_27.148.170102.14","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780300607"},{"key":"2024102403341469000_27.148.170102.15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0002-9343(87)90501-8","article-title":"Longitudinal changes in lung function and respiratory symptoms in progressive systemic sclerosis. Prospective study","volume":"83","author":"Greenwald","year":"1987","journal-title":"Am J Med"},{"key":"2024102403341469000_27.148.170102.16","doi-asserted-by":"publisher","DOI":"10.1016\/0049-0172(88)90012-1"},{"key":"2024102403341469000_27.148.170102.17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000195774","article-title":"Retrospective studies in scleroderma: pulmonary findings and effect of potassium p-aminobenzoate on vital capacity","volume":"56","author":"Zarafonetis","year":"1989","journal-title":"Respiration"},{"key":"2024102403341469000_27.148.170102.18","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90425-D"},{"key":"2024102403341469000_27.148.170102.19","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.67.789.632"},{"key":"2024102403341469000_27.148.170102.20","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.4_Pt_1.1076"},{"key":"2024102403341469000_27.148.170102.21","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1183\/09031936.93.06060797","article-title":"Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis","volume":"6","author":"Wells","year":"1993","journal-title":"Eur Respir J"},{"key":"2024102403341469000_27.148.170102.22","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2214\/ajr.161.6.8249719","article-title":"Serial CT in fibrosing alveolitis: prognostic significance of the initial pattern","volume":"161","author":"Wells","year":"1993","journal-title":"AJR Am J Roentgenol"},{"key":"2024102403341469000_27.148.170102.23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.5.437"},{"key":"2024102403341469000_27.148.170102.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370903"},{"key":"2024102403341469000_27.148.170102.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780370904"},{"key":"2024102403341469000_27.148.170102.26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.2.489"},{"key":"2024102403341469000_27.148.170102.27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000196449","article-title":"Pathogenetic and clinical significance of fibroblast activation in scleroderma lung disease","volume":"62","author":"Behr","year":"1995","journal-title":"Respiration"},{"key":"2024102403341469000_27.148.170102.28","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.154.2.8756813"},{"key":"2024102403341469000_27.148.170102.29","doi-asserted-by":"publisher","DOI":"10.1007\/BF02242456"},{"key":"2024102403341469000_27.148.170102.30","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.3.801"},{"key":"2024102403341469000_27.148.170102.31","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199906)42:6<1168::AID-ANR13>3.0.CO;2-L"},{"key":"2024102403341469000_27.148.170102.32","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1183\/09031936.99.13113399","article-title":"Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis","volume":"13","author":"Kon","year":"1999","journal-title":"Eur Respir J"},{"key":"2024102403341469000_27.148.170102.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.58.10.635"},{"key":"2024102403341469000_27.148.170102.34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.7326\/0003-4819-132-12-200006200-00004","article-title":"Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis","volume":"132","author":"White","year":"2000","journal-title":"Ann Intern Med"},{"key":"2024102403341469000_27.148.170102.35","first-page":"1207","article-title":"The relationship between serum immunoglobulin levels and pulmonary involvement in systemic sclerosis","volume":"27","author":"Yuhara","year":"2000","journal-title":"J Rheumatol"},{"key":"2024102403341469000_27.148.170102.36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/1529-0131(200108)45:4<346::AID-ART347>3.0.CO;2-L","article-title":"Esophageal involvement and pulmonary manifestations in systemic sclerosis","volume":"45","author":"Marie","year":"2001","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024102403341469000_27.148.170102.37","first-page":"503","article-title":"Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study","volume":"19","author":"Scorza","year":"2001","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.38","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2106012"},{"key":"2024102403341469000_27.148.170102.39","first-page":"731","article-title":"Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis","volume":"29","author":"Giacomelli","year":"2002","journal-title":"J Rheumatol"},{"key":"2024102403341469000_27.148.170102.40","first-page":"298","article-title":"Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease","volume":"29","author":"Pakas","year":"2002","journal-title":"J Rheumatol"},{"key":"2024102403341469000_27.148.170102.41","doi-asserted-by":"publisher","DOI":"10.1002\/art.11042"},{"key":"2024102403341469000_27.148.170102.42","first-page":"429","article-title":"Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis","volume":"21","author":"Yanaba","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.43","first-page":"573","article-title":"Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results","volume":"22","author":"Airo","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.44","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"2024102403341469000_27.148.170102.45","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-6-96"},{"key":"2024102403341469000_27.148.170102.46","doi-asserted-by":"publisher","DOI":"10.1002\/art.21257"},{"key":"2024102403341469000_27.148.170102.47","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.033076"},{"key":"2024102403341469000_27.148.170102.48","doi-asserted-by":"publisher","DOI":"10.1002\/art.22204"},{"key":"2024102403341469000_27.148.170102.49","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.22099","article-title":"Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline","volume":"55","author":"Plastiras","year":"2006","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024102403341469000_27.148.170102.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2024102403341469000_27.148.170102.51","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2007.03.005"},{"key":"2024102403341469000_27.148.170102.52","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0254-x"},{"key":"2024102403341469000_27.148.170102.53","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.069518"},{"key":"2024102403341469000_27.148.170102.54","doi-asserted-by":"publisher","DOI":"10.1002\/art.22696"},{"key":"2024102403341469000_27.148.170102.55","doi-asserted-by":"publisher","DOI":"10.1002\/art.23077"},{"key":"2024102403341469000_27.148.170102.56","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200702-326OC"},{"key":"2024102403341469000_27.148.170102.57","first-page":"734","article-title":"Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease","volume":"25","author":"Tzelepis","year":"2007","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.58","first-page":"1064","article-title":"Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study","volume":"35","author":"Berezne","year":"2008","journal-title":"J Rheumatol"},{"key":"2024102403341469000_27.148.170102.59","doi-asserted-by":"publisher","DOI":"10.1002\/art.23406"},{"key":"2024102403341469000_27.148.170102.60","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200706-877OC"},{"key":"2024102403341469000_27.148.170102.61","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200705-655OC"},{"key":"2024102403341469000_27.148.170102.62","first-page":"443","article-title":"The whole blood interferon score predicts progression of interstitial lung disease in systemic sclerosis","volume":"60","author":"Assassi","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024102403341469000_27.148.170102.63","doi-asserted-by":"publisher","DOI":"10.1159\/000156958"},{"key":"2024102403341469000_27.148.170102.64","first-page":"606","article-title":"Imatinib mesylate (Gleevec) in the treatment of systemic sclerosis: interim results of a phase IIa, one year, open label clinical trial","volume":"60","author":"Gordon","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2024102403341469000_27.148.170102.65","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep284"},{"key":"2024102403341469000_27.148.170102.66","first-page":"i76","article-title":"Long-term outcome of a targeted treatment regimen with IV cyclophosphamide (CYC) in patients with systemic sclerosis (SSC) and interstitial lung disease (ILD)","volume":"48","author":"Ottewell","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2024102403341469000_27.148.170102.67","doi-asserted-by":"publisher","DOI":"10.1186\/ar2766"},{"key":"2024102403341469000_27.148.170102.68","doi-asserted-by":"publisher","DOI":"10.1111\/j.1756-185X.2009.01417.x"},{"key":"2024102403341469000_27.148.170102.69","doi-asserted-by":"publisher","DOI":"10.1186\/ar3125"},{"key":"2024102403341469000_27.148.170102.70","first-page":"1989","article-title":"Circulating T cell polarization is associated with respiratory decline in scleroderma patients with active interstitial lung disease","volume":"62","author":"Boin","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024102403341469000_27.148.170102.71","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3109\/03009740903270581","article-title":"Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis","volume":"39","author":"Colaci","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"2024102403341469000_27.148.170102.72","first-page":"S167","article-title":"Mycophenolate mophetil in the treatment of systemic sclerosis-interstitial lung disease (SSc-ILD) in patients unresponsive to cyclophosphamide (CYC)","volume":"28","author":"Cuomo","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.73","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00060209"},{"key":"2024102403341469000_27.148.170102.74","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.129601g"},{"key":"2024102403341469000_27.148.170102.75","first-page":"S76","article-title":"Long-term outcome of patients with an isolated low diffusing capacity","volume":"28","author":"Schorr","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.76","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024102403341469000_27.148.170102.77","first-page":"592","article-title":"Scleroderma lung disease: effect of co-existent pulmonary hypertension on progression of interstitial lung disease","volume":"62","author":"Shahane","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024102403341469000_27.148.170102.78","first-page":"1231","article-title":"Severe pulmonary fibrosis is uncommon in scleroderma patients with RNA polymerase 3 antibody","volume":"62","author":"Steen","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2024102403341469000_27.148.170102.79","first-page":"S78","article-title":"A preliminary investigation of the predictive value and response to therapy with cyclophosphamide of interleukin-16 in bronchoalveolar lavage from patients with interstitial lung disease in systemic sclerosis","volume":"28","author":"Theodore","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.80","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10067-011-1734-1","article-title":"Outcome of systemic sclerosis associated interstitial lung disease treated with intravenous cyclophosphamide","volume":"30","author":"Abhishek","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2024102403341469000_27.148.170102.81","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-22"},{"key":"2024102403341469000_27.148.170102.82","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.arbres.2011.01.010","article-title":"Efficacy of cyclophospamide in the treatment of interstitial lung disease associated with systemic sclerosis","volume":"47","author":"Espinosa","year":"2011","journal-title":"Arch Bronconeumol"},{"key":"2024102403341469000_27.148.170102.83","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00010910"},{"key":"2024102403341469000_27.148.170102.84","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100591"},{"key":"2024102403341469000_27.148.170102.85","doi-asserted-by":"publisher","DOI":"10.1002\/art.30415"},{"key":"2024102403341469000_27.148.170102.86","first-page":"11","article-title":"Mycophenolate mofetil (MMF) in scleroderma (SSC) associated interstitial lung disease (ILD) and skin disease\u2013the Australian experience","volume":"41","author":"Jayaweera","year":"2011","journal-title":"Intern Med J"},{"key":"2024102403341469000_27.148.170102.87","doi-asserted-by":"publisher","DOI":"10.1002\/art.30548"},{"key":"2024102403341469000_27.148.170102.88","doi-asserted-by":"publisher","DOI":"10.1002\/art.30467"},{"key":"2024102403341469000_27.148.170102.89","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1874312901105010001","article-title":"Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease","volume":"5","author":"Mittoo","year":"2011","journal-title":"Open Rheumatol J"},{"key":"2024102403341469000_27.148.170102.90","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1007\/s00296-010-1501-7","article-title":"Pulmonary survival study in 91 patients with systemic sclerosis","volume":"31","author":"Poormoghim","year":"2011","journal-title":"Rheumatol Int"},{"key":"2024102403341469000_27.148.170102.91","doi-asserted-by":"publisher","DOI":"10.1177\/039463201102400319"},{"key":"2024102403341469000_27.148.170102.92","doi-asserted-by":"publisher","DOI":"10.1002\/art.30438"},{"key":"2024102403341469000_27.148.170102.93","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00004711"},{"key":"2024102403341469000_27.148.170102.94","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s00296-010-1390-9","article-title":"Bronchoalveolar lavage in systemic sclerosis with lung involvement: role and correlations with functional, radiological and scintigraphic parameters","volume":"31","author":"Volpinari","year":"2011","journal-title":"Rheumatol Int"},{"key":"2024102403341469000_27.148.170102.95","first-page":"ii114","article-title":"Extended course cyclophosphamide and methylprednisolone pulse therapy can stabilize initially refractory interstitial lung disease in patients with SSc: a single-centre experience","volume":"51","author":"Abignano","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2024102403341469000_27.148.170102.96","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2010.00228.x"},{"key":"2024102403341469000_27.148.170102.97","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker442"},{"key":"2024102403341469000_27.148.170102.98","first-page":"S27","article-title":"Outcome of immunosuppressive therapy in patients with scleroderma and interstitial lung disease, 2 years follow up data, a retrospective study","volume":"7","author":"Kishore Babu","year":"2012","journal-title":"Indian J Rheumatol"},{"key":"2024102403341469000_27.148.170102.99","first-page":"ii83","article-title":"Natural history of pulmonary function in patients with SSc and interstitial lung disease","volume":"51","author":"Kuwana","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2024102403341469000_27.148.170102.100","first-page":"S371","article-title":"Elevation of KL-6 at early disease course predicts subsequent deterioration of pulmonary function in patients with systemic sclerosis and interstitial lung disease","volume":"64","author":"Kuwana","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2024102403341469000_27.148.170102.101","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.148262"},{"key":"2024102403341469000_27.148.170102.102","first-page":"P692","article-title":"CCL18 as marker of disease progression in systemic sclerosis","volume":"40","author":"Schupp","year":"2012","journal-title":"Eur Respir J"},{"key":"2024102403341469000_27.148.170102.103","first-page":"S71","article-title":"CXCL11 in bronchoalveolar lavage fluid and pulmonary function decline in systemic sclerosis","volume":"30","author":"Sfriso","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.104","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/annrheumdis-2012-eular.2556","article-title":"Pulmonary fibrosis and connective tissue diseases: follow-up of lung involvement in rheumatoid arthritis and systemic sclerosis","volume":"71","author":"Soriano","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.105","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2011-200499"},{"key":"2024102403341469000_27.148.170102.106","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1136\/annrheumdis-2013-eular.1924","article-title":"Rituximab for the treatment of systemic sclerosis associated interstitial lung disease: a case series","volume":"72","author":"Ananyeva","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.107","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.resinv.2012.12.002","article-title":"Effect of glucocorticoid monotherapy on pulmonary function and survival in Japanese patients with scleroderma-related interstitial lung disease","volume":"51","author":"Ando","year":"2013","journal-title":"Respir Investig"},{"key":"2024102403341469000_27.148.170102.108","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62114-X"},{"key":"2024102403341469000_27.148.170102.109","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2013.04.004"},{"key":"2024102403341469000_27.148.170102.110","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120725"},{"key":"2024102403341469000_27.148.170102.111","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120997"},{"key":"2024102403341469000_27.148.170102.112","first-page":"A2919","article-title":"Does the immunosuppressive therapy modify the pulmonary function parameters in interstitial lung disease (ILD) associated with scleroderma: our experience","volume":"187","author":"Enghelmayer","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403341469000_27.148.170102.113","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1936"},{"key":"2024102403341469000_27.148.170102.114","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1002\/acr.21968","article-title":"Does C-reactive protein predict the long-term progression of interstitial lung disease and survival in patients with early systemic sclerosis?","volume":"65","author":"Liu","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2024102403341469000_27.148.170102.115","doi-asserted-by":"publisher","DOI":"10.1007\/s00408-013-9499-8"},{"key":"2024102403341469000_27.148.170102.116","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1506"},{"key":"2024102403341469000_27.148.170102.117","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201786"},{"key":"2024102403341469000_27.148.170102.118","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-eular.1511"},{"key":"2024102403341469000_27.148.170102.119","first-page":"S742","article-title":"Plasma MCP-1 and IL-10 levels predict long-term progression of interstitial lung disease in patients with early systemic sclerosis","volume":"65","author":"Wu","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024102403341469000_27.148.170102.120","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120705"},{"key":"2024102403341469000_27.148.170102.121","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1136\/annrheumdis-2014-eular.3488","article-title":"Slow progressive interstitial lung disease associated with systemic sclerosis: distinct disease phenotype?","volume":"73","author":"Ananyeva","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.122","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1136\/annrheumdis-2014-eular.3044","article-title":"Long-term effectiveness and safety of cyclophosphamide in systemic sclerosis lung disease","volume":"73","author":"Chakr","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.123","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","article-title":"Association of interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis","volume":"66","author":"Christmann","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.124","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202849"},{"key":"2024102403341469000_27.148.170102.125","doi-asserted-by":"publisher","DOI":"10.1186\/ar4606"},{"key":"2024102403341469000_27.148.170102.126","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.07.002"},{"key":"2024102403341469000_27.148.170102.127","first-page":"S316","article-title":"Moderate decline in forced vital capacity is associated with a poor outcome in systemic sclerosis patients","volume":"66","author":"Hoffmann-Vold","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.128","first-page":"S138","article-title":"Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis","volume":"32","author":"Kumanovics","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.129","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2014-eular.4302","article-title":"Efficacy and safety of long term cyclophosphamide treatment for interstitial lung disease in systemic sclerosis","volume":"73","author":"Kwon","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.130","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/art.38241","article-title":"Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development","volume":"66","author":"Lambrecht","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.131","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1136\/annrheumdis-2014-eular.3866","article-title":"Prognostic factors of functional outcome in systemic sclerosis-associated interstitial lung disease","volume":"73","author":"Le Gouellec","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.132","first-page":"S737","article-title":"Long-term efficacy of rituximab in systemic sclerosis","volume":"66","author":"Narvaez","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.133","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.134","first-page":"S739","article-title":"A double blind randomized control trial of oral tadalafil in interstitial lung disease of scleroderma","volume":"66","author":"Parida","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.135","first-page":"S742","article-title":"Effects of mycophenolate mofetil on pulmonary lung function in interstitial lung disease of systemic sclerosis","volume":"66","author":"Pham","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.136","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00296-014-3026-y","article-title":"Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement\u2013a retrospective study","volume":"34","author":"Poormoghim","year":"2014","journal-title":"Rheumatol Int"},{"key":"2024102403341469000_27.148.170102.137","first-page":"S83","article-title":"Residual volume: a candidate as early marker of interstitial lung disease in systemic sclerosis patients?","volume":"32","author":"Rotondo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.138","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203803"},{"key":"2024102403341469000_27.148.170102.139","first-page":"150","article-title":"Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience","volume":"17","author":"Balbir-Gurman","year":"2015","journal-title":"Isr Med Assoc J"},{"key":"2024102403341469000_27.148.170102.140","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.09.002"},{"key":"2024102403341469000_27.148.170102.141","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev204"},{"key":"2024102403341469000_27.148.170102.142","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.143","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2014.09.003"},{"key":"2024102403341469000_27.148.170102.144","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522"},{"key":"2024102403341469000_27.148.170102.145","first-page":"816","article-title":"Safety and tolerability of pirfenidone in patients with systemic sclerosis interstitial lung disease","volume":"67","author":"Khanna","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.146","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-015-0872-2"},{"key":"2024102403341469000_27.148.170102.147","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204361"},{"key":"2024102403341469000_27.148.170102.148","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/annrheumdis-2015-eular.6310","article-title":"Mid-term effects of rituximab in connective tissue disorders related interstitial lung disease (ILD)","volume":"74","author":"Lepri","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.149","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev016"},{"key":"2024102403341469000_27.148.170102.150","first-page":"114","article-title":"Rituximab in systemic sclerosis with ILD-two year outcome from a tertiary care hospital in South India","volume":"18","author":"Mani","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"2024102403341469000_27.148.170102.151","first-page":"A1158","article-title":"Functional follow-up of diffuse interstitial lung disease (ILD) in phenotypes of systemic sclerosis (SSC)","volume":"191","author":"Mateos-Toledo","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403341469000_27.148.170102.152","first-page":"2267","article-title":"Is the presence of esophageal dilation a poor prognostic factor in dilated interstitial lung disease associated with systemic sclerosis?","volume":"67","author":"Narvaez","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.153","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2015.01.012"},{"key":"2024102403341469000_27.148.170102.154","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2015-eular.6092","article-title":"Does angiotensin and endothelin receptor blockade have an impact on lung function? An analysis from the EUSTAR data base","volume":"74","author":"Radic","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.155","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12931-015-0308-1","article-title":"Association of elevated \u03b1-defensin levels with interstitial pneumonia in patients with systemic sclerosis","volume":"16","author":"Sakamoto","year":"2015","journal-title":"Respir Res"},{"key":"2024102403341469000_27.148.170102.156","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/annrheumdis-2015-eular.3483","article-title":"Mycophenolate mofetil (MMF) use in scleroderma patients with pulmonary hypertension: FVC, outcomes and survival-observations from the Pulmonary Hypertension Recognition and Outcomes in Scleroderma (PHAROS) cohort","volume":"74","author":"Saketkoo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.157","first-page":"1123","article-title":"A computational tool for individualized prognosis of percent of predicted forced vital capacity trajectories in systemic sclerosis","volume":"67","author":"Schulam","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.158","first-page":"115","article-title":"Clinical utility of serial KL-6 measurement in interstitial lung disease associated with systemic sclerosis","volume":"67","author":"Shirai","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.159","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.160","first-page":"941","article-title":"Lactate dehydrogenase a possible marker of progressive microvasculopathy and interstitial lung disease in systemic sclerosis","volume":"31","author":"Tanaseanu","year":"2015","journal-title":"Acta Med Mediterr"},{"key":"2024102403341469000_27.148.170102.161","doi-asserted-by":"crossref","first-page":"637A","DOI":"10.1378\/chest.2331164","article-title":"Efficacy and safety of mycophenolate (MMF) vs oral cyclophosphamide (CYC) for treatment of scleroderma-interstitial lung disease (SscILD): results of scleroderma lung study II","volume":"148","author":"Tashkin","year":"2015","journal-title":"Chest"},{"key":"2024102403341469000_27.148.170102.162","doi-asserted-by":"crossref","first-page":"1000154","DOI":"10.4172\/2161-1149.1000154","article-title":"Development of a composite outcome measure for systemic sclerosis related interstitial lung disease","volume":"5","author":"Volkmann","year":"2015","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2024102403341469000_27.148.170102.163","first-page":"1406","article-title":"CXCL4 does not predict extent or progression of interstitial lung disease in systemic sclerosis","volume":"67","author":"Volkmann","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.164","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu456"},{"key":"2024102403341469000_27.148.170102.165","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-016-0993-2","article-title":"Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma","volume":"18","author":"Fava","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024102403341469000_27.148.170102.166","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.chest.2016.03.004","article-title":"High level of chemokine CCL18 is associated with pulmonary function deterioration, lung fibrosis progression and reduced survival in systemic sclerosis","volume":"150","author":"Hoffmann-Vold","year":"2016","journal-title":"Chest"},{"key":"2024102403341469000_27.148.170102.167","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew259"},{"key":"2024102403341469000_27.148.170102.168","first-page":"170","article-title":"Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study","volume":"34","author":"Owen","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.169","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-016-1015-0","article-title":"Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis","volume":"18","author":"Shenoy","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2024102403341469000_27.148.170102.170","unstructured":"U.S. National Library of Medicine (ClinicalTrials.gov) . Open-label study with bosentan in interstitial lung disease (BUILD 2 OL). http:\/\/clinicaltrials.gov\/show\/NCT00319033 Date last updated: April 28, 2015. Date last accessed: February 23, 2017."},{"key":"2024102403341469000_27.148.170102.171","unstructured":"EU Clinical Trials Register . Systemic sclerosis associated interstitial lung disease: a longitudinal observational study assessing optimum treatment regimens. www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2008-000224-27 Date last accessed: February 23, 2017."},{"key":"2024102403341469000_27.148.170102.172","unstructured":"U.S. National Library of Medicine (ClinicalTrials.gov) . Intravenous cyclophosphamide for the treatment of systemic sclerosis associated interstitial lung disease. https:\/\/clinicaltrials.gov\/show\/NCT01570764 Date last updated: September 14, 2016. Date last accessed: February 23, 2017."},{"key":"2024102403341469000_27.148.170102.173","unstructured":"U.S. National Library of Medicine (ClinicalTrials.gov) . Study of pomalidomide (CC-4047) to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and effectiveness for subjects with systemic sclerosis with interstitial lung disease. https:\/\/clinicaltrials.gov\/show\/NCT01559129 Date last updated: April 05, 2017. Date last accessed: February 23, 2017."},{"key":"2024102403341469000_27.148.170102.174","unstructured":"U.S. National Library of Medicine (ClinicalTrials.gov) . Treatment and prevention of progression of interstitial lung disease in systemic sclerosis. http:\/\/clinicaltrials.gov\/show\/NCT01858259 Date last updated: August 12, 2014. Date last accessed: February 24, 2017."},{"key":"2024102403341469000_27.148.170102.175","unstructured":"U.S. National Library of Medicine (ClinicalTrials.gov) . A trial to compare nintedanib with placebo for patients with scleroderma related lung fibrosis. https:\/\/clinicaltrials.gov\/show\/NCT02597933 Date last updated: August 21, 2017. Date last accessed: February 23, 2017."},{"key":"2024102403341469000_27.148.170102.176","unstructured":"U.S. National Library of Medicine (ClinicalTrials.gov) . A double-blinded study to evaluate the safety, tolerability, and efficacy of BMS-986020 versus placebo in diffuse cutaneous systemic sclerosis (dcSSc). https:\/\/clinicaltrials.gov\/show\/NCT02588625 Date last updated: July 20, 2016. Date last accessed: February 23, 2017."},{"key":"2024102403341469000_27.148.170102.177","unstructured":"U.S. National Library of Medicine (ClinicalTrials.gov) . Comparing and combining bortezomib and mycophenolate in SSc pulmonary fibrosis. https:\/\/clinicaltrials.gov\/show\/NCT02370693 Date last updated: January 20, 2017. Date last accessed: February 24, 2017."},{"key":"2024102403341469000_27.148.170102.178","unstructured":"U.S. National Library of Medicine (ClinicalTrials.gov) . Abituzumab in SSc-ILD. https:\/\/clinicaltrials.gov\/show\/NCT02745145 Date last updated: July 27, 2017. Date last accessed: February 24, 2017."},{"key":"2024102403341469000_27.148.170102.179","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/144.3_Pt_1.706"},{"key":"2024102403341469000_27.148.170102.180","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1229::AID-ART6>3.0.CO;2-W"},{"key":"2024102403341469000_27.148.170102.181","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.97.10020280"},{"key":"2024102403341469000_27.148.170102.182","doi-asserted-by":"publisher","DOI":"10.1378\/chest.114.6.1623"},{"key":"2024102403341469000_27.148.170102.183","doi-asserted-by":"publisher","DOI":"10.1097\/00004728-200109000-00015"},{"key":"2024102403341469000_27.148.170102.184","doi-asserted-by":"publisher","DOI":"10.1007\/s002960000089"},{"key":"2024102403341469000_27.148.170102.185","first-page":"230","article-title":"DLCO as a predictor of pulmonary fibrosis on high resolution CT in systemic sclerosis","volume":"62","author":"Han","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.186","doi-asserted-by":"publisher","DOI":"10.1080\/j.1600-0455.2003.00058.x"},{"key":"2024102403341469000_27.148.170102.187","doi-asserted-by":"publisher","DOI":"10.1097\/01.rct.0000228159.86096.47"},{"key":"2024102403341469000_27.148.170102.188","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel221"},{"key":"2024102403341469000_27.148.170102.189","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-1401"},{"key":"2024102403341469000_27.148.170102.190","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-2444"},{"key":"2024102403341469000_27.148.170102.191","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-009-0367-9"},{"key":"2024102403341469000_27.148.170102.192","doi-asserted-by":"publisher","DOI":"10.1378\/chest.09-0108"},{"key":"2024102403341469000_27.148.170102.193","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091710"},{"key":"2024102403341469000_27.148.170102.194","first-page":"S151","article-title":"Relationship between computed tomography and lung function parameters in patients with different duration of systemic sclerosis","volume":"28","author":"Ananyeva","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.195","first-page":"S150","article-title":"Pulmonary involvement in Chinese patients with SSc and correlations between the imaging and functional abnormalities","volume":"28","author":"Peng","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.196","first-page":"1440","article-title":"Association of texture-based quantitative fibrotic patterns and pulmonary function test in a new validation set","volume":"38","author":"Kim","year":"2011","journal-title":"Eur Respir J"},{"key":"2024102403341469000_27.148.170102.197","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-011-2223-2"},{"key":"2024102403341469000_27.148.170102.198","first-page":"22","article-title":"Assessments of pulmonary involvement in patients with systemic sclerosis","volume":"14","author":"Moghadam","year":"2011","journal-title":"Arch Iran Med"},{"key":"2024102403341469000_27.148.170102.199","first-page":"S144","article-title":"Increase alpha-smooth muscle actin, telomerase, interleukin-4 and endothelin-1 expression in progressive pulmonary fibrosis of systemic sclerosis (SSc)","volume":"459","author":"Parra","year":"2011","journal-title":"Virchows Archiv"},{"key":"2024102403341469000_27.148.170102.200","first-page":"A6616","article-title":"Clinical correlates of lung scan abnormalities in patients with systemic sclerosis-associated interstitial lung disease","volume":"185","author":"Assayag","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403341469000_27.148.170102.201","first-page":"ii69","article-title":"Cytokines panel in exhaled breath condensate in SSc","volume":"51","author":"Mantero","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2024102403341469000_27.148.170102.202","first-page":"S5","article-title":"HRCT chest score and bronchoalveolar lavage fluid cytology in assessment of disease activity of systemic sclerosis associated interstitial lung disease","volume":"7","author":"Mittal","year":"2012","journal-title":"Indian J Rheumatol"},{"key":"2024102403341469000_27.148.170102.203","doi-asserted-by":"publisher","DOI":"10.1159\/000335473"},{"key":"2024102403341469000_27.148.170102.204","first-page":"ii71","article-title":"Membrane diffusion and capillary blood volume measurements in patients with SSc","volume":"51","author":"Perrin","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2024102403341469000_27.148.170102.205","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2012.02133.x"},{"key":"2024102403341469000_27.148.170102.206","first-page":"ii46","article-title":"Semiquantitative evaluation of high resolution CT in SSc: preliminary applicability of a simple score in clinical practice","volume":"51","author":"Zimmermann","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2024102403341469000_27.148.170102.207","first-page":"579","article-title":"HRCT in systemic sclerosis: correlation between respiratory functional indexes and extension of lung failure","volume":"27","author":"Gatta","year":"2013","journal-title":"J Biol Regul Homeost Agents"},{"key":"2024102403341469000_27.148.170102.208","first-page":"W74","article-title":"Histogram-based quantification of fibrosis in systemic sclerosis on sequential low dose HRCT of 9 CT slices","volume":"28","author":"Nguyen-Kim","year":"2013","journal-title":"J Thorac Imaging"},{"key":"2024102403341469000_27.148.170102.209","doi-asserted-by":"crossref","unstructured":"Piorunek T , Kuznar-Kaminska B , Cofta S , et al. Lung impairment in scleroderma. In: Pokorski M , ed. Respiratory regulation\u2013clinical advances . New York, Springer, 2013; pp. 149\u2013154.","DOI":"10.1007\/978-94-007-4546-9_20"},{"key":"2024102403341469000_27.148.170102.210","first-page":"A2920","article-title":"Prevalence of pulmonary function test abnormalities and their correlation to high resolution computer tomography in a large scleroderma population","volume":"187","author":"Zamora","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403341469000_27.148.170102.211","first-page":"481","article-title":"Lung involvement in systemic sclerosis: role of high resolution computed tomography and its relationship with other pulmonary and clinico-serological features","volume":"28","author":"Colaci","year":"2014","journal-title":"J Biol Regul Homeost Agents"},{"key":"2024102403341469000_27.148.170102.212","doi-asserted-by":"crossref","first-page":"724","DOI":"10.3109\/14397595.2015.1016200","article-title":"Operator-independent quantitative chest computed tomography versus standard assessment of interstitial lung disease related to systemic sclerosis: a multi-centric study","volume":"25","author":"Ariani","year":"2015","journal-title":"Mod Rheumatol"},{"key":"2024102403341469000_27.148.170102.213","first-page":"2268","article-title":"The predictive value of pulmonary function tests to diagnose interstitial lung disease in adults with early diffuse cutaneous systemic sclerosis","volume":"67","author":"Bernstein","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.214","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1136\/annrheumdis-2015-eular.4312","article-title":"MDCT staging of disease extent in patients with systemic sclerosis: a pilot study","volume":"74","author":"Ghandour","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2024102403341469000_27.148.170102.215","first-page":"S80","article-title":"Determinants of impairment in lung diffusing capacity in patients with systemic sclerosis","volume":"33","author":"Guarnieri","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.216","first-page":"A1161","article-title":"Systemic sclerosis interstitial lung disease evaluation: comparison between two quantitative computed tomography for the change assessments","volume":"191","author":"Kim","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403341469000_27.148.170102.217","doi-asserted-by":"crossref","unstructured":"Salaffi F , Carotti M , Bosello S , et al. Computer-aided quantification of interstitial lung disease from high resolution computed tomography images in systemic sclerosis: correlation with visual reader-based score and physiologic tests. Biomed Res Int 2015: 834262.","DOI":"10.1155\/2015\/834262"},{"key":"2024102403341469000_27.148.170102.218","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/art.39528","article-title":"Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension","volume":"68","author":"Antoniou","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.219","first-page":"50","article-title":"Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis","volume":"6","author":"Cetincakmak","year":"2016","journal-title":"Quant Imaging Med Surg"},{"key":"2024102403341469000_27.148.170102.220","doi-asserted-by":"crossref","first-page":"e0149240","DOI":"10.1371\/journal.pone.0149240","article-title":"Computer-aided tomographic analysis of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Correlation with pulmonary physiologic tests and patient-centred measures of perceived dyspnea and functional disability","volume":"11","author":"Salaffi","year":"2016","journal-title":"PLoS One"},{"key":"2024102403341469000_27.148.170102.221","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206076"},{"key":"2024102403341469000_27.148.170102.222","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60405-4"},{"key":"2024102403341469000_27.148.170102.223","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2024102403341469000_27.148.170102.224","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202640"},{"key":"2024102403341469000_27.148.170102.225","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201201-0006PP"},{"key":"2024102403341469000_27.148.170102.226","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1002\/art.38702","article-title":"Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?","volume":"66","author":"Herzog","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024102403341469000_27.148.170102.227","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken311"},{"key":"2024102403341469000_27.148.170102.228","doi-asserted-by":"publisher","DOI":"10.2174\/157339710791330768"},{"key":"2024102403341469000_27.148.170102.229","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of forced vital capacity: results from the Scleroderma Lung Studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102403341469000_27.148.170102.230","first-page":"1194","article-title":"Systemic sclerosis-continuing progress in developing clinical measures of response","volume":"34","author":"Furst","year":"2007","journal-title":"J Rheumatol"},{"key":"2024102403341469000_27.148.170102.231","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00035205"},{"key":"2024102403341469000_27.148.170102.232","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2024102403341469000_27.148.170102.233","doi-asserted-by":"publisher","DOI":"10.1183\/09059180.00005512"},{"key":"2024102403341469000_27.148.170102.234","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.141182"},{"key":"2024102403341469000_27.148.170102.235","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2626"},{"key":"2024102403341469000_27.148.170102.236","first-page":"S111","article-title":"Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease","volume":"33","author":"Moore","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"2024102403341469000_27.148.170102.237","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"}],"container-title":["European Respiratory Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/16000617.0102-2017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T15:15:31Z","timestamp":1751642131000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/16000617.0102-2017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":237,"journal-issue":{"issue":"148","published-online":{"date-parts":[[2018,5,15]]},"published-print":{"date-parts":[[2018,6,30]]}},"alternative-id":["10.1183\/16000617.0102-2017"],"URL":"https:\/\/doi.org\/10.1183\/16000617.0102-2017","relation":{},"ISSN":["0905-9180","1600-0617"],"issn-type":[{"value":"0905-9180","type":"print"},{"value":"1600-0617","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]}}}